Short answer
PUMA BIOTECHNOLOGY, INC. (PBYI) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $55M (up 1.1% year over year) with net income of $6M.
Q3 2026 key financials · XBRL
- Revenue
- $55M
- +1.1% YoY · −2.6% QoQ
- Net income
- $6M
- −32.7% YoY · −27.3% QoQ
- Operating margin
- 9.6%
- EPS (diluted)
- $0.12
- −29.4% YoY · −20.0% QoQ
Source: XBRL data from the PUMA BIOTECHNOLOGY, INC. (PBYI) Q3 2026 10-Q on SEC EDGAR. USD.
PUMA BIOTECHNOLOGY, INC. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $55.1M, up from $54.5M YoY, driven by product revenue of $54.1M vs $51.9M
- Product revenue best performer, up $2.2M; royalty revenue weakest, $0.9M vs $2.6M
- Gross margin 72.4% vs 77.6% YoY; net margin 10.8% vs 16.2%
- Operating cash flow $31.6M for nine months vs $27.4M; cash $41.5M plus securities $67.0M
- Alisertib spending rising; debt fully repaid, while tariffs and China royalty-rate reduction remain headwinds
Risk Factors
- No material changes to risk factors since the December 31, 2025 Form 10-K
- Unknown or currently immaterial risks could still materially affect results
- Forward-looking statements remain subject to actual results differing materially from expectations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PUMA BIOTECHNOLOGY, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.